FDA-Approved Ovarian Cancer Drug Treatments

Share this content:
FDA-APPROVED OVARIAN CANCER TREATMENTS
FDA-APPROVED OVARIAN CANCER TREATMENTS
Generic Brand Strength Form Usual Dose
Alkylating agent
altretamine Hexalen 50mg caps 260mg/m² daily in four divided doses for either 14 or 21 consecutive days in a 28-day cycle
carboplatin 10mg/
 
mL
soln for IV infusion Advanced ovarian cancer (previously untreated): 300mg/m² on Day 1 every 4wks for 6 cycles
Recurrent ovarian cancer: 360mg/m² on Day 1 every 4wks
cisplatin 1mg/mL soln for IV infusion after dilution 100mg/m² once every 4wks
cyclophos-
phamide
25mg, 50mg tabs 1–5mg/kg/day
500mg, 1g, 2g pwd for inj after reconsti-
tution
40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan Alkeran 2mg scored tabs 0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa 15mg pwd for IV, intravesical, or intracavitary admini-
stration after reconsti-
tution
0.3–0.4mg/kg IV once every 1–4wks
Antibiotics (cytotoxic)
doxorubicin 10mg, 20mg, 50mg pwd for IV inj after reconsti-
tution
Monotherapy: 60–75mg/m² every 21 days
Combination therapy: 40–60mg/m² every 21 to 28 days
2mg/mL soln for IV inj
doxorubicin (liposomal) Doxil 2mg/mL dispersion for IV infusion after dilution 50mg/m² once every 4wks
Antimetabolite
gemcitabine Gemzar 200mg, 1g pwd for IV infusion after reconsti-
tution
1000mg/m² on Days 1 and 8 of each 21-day cycle
Antimicrotubule agents
paclitaxel Taxol 6mg/mL soln for IV admini-
stration after dilution
Previously untreated ovarian cancer: 175mg/m² over 3hrs or 135mg/m² over 24hrs; repeat every 3wks
Previously treated ovarian cancer: 135mg/m² or 175mg/m² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR
olaparib Lynparza* 50mg caps 400mg twice daily until disease progression or unacceptable toxicity; max 800mg daily
100mg, 150mg tabs 300mg twice daily until disease progression or unacceptable toxicity; max 600mg daily
rucaparib Rubraca* 200mg, 250mg, 300mg tabs 600mg twice daily until disease progression or unacceptable toxicity
Topoisomerase inhibitor
topotecan Hycamtin 4mg pwd for IV infusion after reconsti-
tution and dilution
1.5mg/m² daily for 5 consecutive days starting on Day 1 of a 21-day cycle
NOTES

*For patients with deleterious BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer.

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 6/2018)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs